Article Per Year (5 Year)
p-Index From 2020 - 2025
0.562
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Higea Journal of Pharmaceutical and Sciences. Medical Sains : Jurnal Ilmiah Kefarmasian
Maulina, Fariha Mufidah
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Sintesis Etil 4-(3,5-dimetil-4-fenoksifenil)-6-metil-2-okso-1,2,3,4-tetrahidropirimidin-5-Karboksilat dan Uji Aktivitas Sitotoksik Terhadap Sel T47D Maulina, Fariha Mufidah; Fauzi, Ahmad; Ramadhan, Muhammad Reza; Hakimah, Wafiq Kholifatul
Journal of Pharmaceutical and Sciences JPS Volume 8 Nomor 2 (2025)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v8i2.772

Abstract

Cancer is one of the biggest health problems in the world, including in Indonesia. Previous studies have found that DHPM compounds have various pharmacological activities such as anticancer, antifungal, antibacterial, antituberculosis, and antioxidant. Based on this potential, it is interesting to conduct further research with the aim of synthesizing and developing new Dihydropyrimidinone (DHPM) compound derivatives that have potential as anticancer. The synthesis of DHPM derivatives was carried out to obtain ethyl 4-(4-hydroxy-3,5-dimethylphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (M1). Then the compound was developed by Mitsunobu reaction using a sonicator to obtain a new compound ethyl 4-(3,5-dimethyl-4-phenoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (C2) which will be tested for cytotoxic activity against T47D cancer cells. Characterization of the compound was done using FT-IR, LC-MS, and melting point. Cytotoxic test against T47D cells as anticancer agent using MTT method [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide] assay. The test results of compound C2 had cytotoxic activity with IC50 of 202.22 µg/mL. The results showed that compound C2 has cytotoxic activity but it is mild because the IC50 produced is high. These findings suggest that compound C2 has anticancer potential, but further structure optimization is needed to increase its effectiveness.
SYNTHESIS OF DIHYDROPYRIMIDINONE DERIVATIVES AND CYTOTOXIC ACTIVITY TEST AGAINST T47D CANCER CELLS Hakimah, Wafiq Kholifatul; Fauzi, Ahmad; Ramadhan, Muhammad Reza; Maulina, Fariha Mufidah
Medical Sains : Jurnal Ilmiah Kefarmasian Vol 10 No 2 (2025)
Publisher : Universitas Muhammadiyah Ahmad Dahlan Cirebon

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37874/ms.v10i2.1693

Abstract

Dihydropyrimidinone (DHPM) derivatives are heterocyclic compounds known for a variety of biological activities including anticancer properties. The Mitsunobu reaction was used in this study to synthesize a new DHPM derivative, ethyl 4-(4-isopropoxy-3,5-dimethylphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (compound B2), and assess its cytotoxic activity against T47D breast cancer cells. Compound B2 was synthesized from ethyl 4-(4-hydroxy-3,5-dimethylphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (compound M1) using multicomponent reactions (MCR) and the Mitsunobu reaction with isopropyl alcohol as the pronucleophile. Compound B2 was characterized using melting point test, FTIR and LC-MS spectroscopy, which confirmed its structure, functional groups, and molecular weight of 334.13 g/mol. MTT assay was used to evaluate cytotoxic activity. Compound B2 had an IC50 value of 205.71 µg/mL, indicating weak cytotoxicity, whereas doxorubicin had an IC50 value of 3.33 µg/mL. Despite the low cytotoxicity of compound B2, this synthesis sheds light on the development of DHPM derivatives with potential anticancer properties. The results showed that the Mitsunobu reaction is useful for modifying DHPM derivatives and highlights the need for further optimization to improve cytotoxic potency. Keywords: Dihydropyrimidinone, Mitsunobu, Cytotoxicity, T47D
SINTESIS DAN UJI AKTIVITAS SITOTOKSIK SENYAWA ETIL 4-(4-ETOKSI-3,5- DIMETILFENIL)-6-METIL-2-OKSO-1,2,3,4-TETRAHIDROPIRIMIDIN-5-KARBOKSILAT TERHADAP SEL T47D Ramadhan, Muhammad Reza; Fauzi, Ahmad; Maulina, Fariha Mufidah; Hakimah, Wafiq Kholifatul
Jurnal Farmasi Higea Vol 17, No 1 (2025)
Publisher : STIFARM Padang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52689/higea.v17i1.702

Abstract

Dihidropirimidinon (DHPM) adalah senyawa heterosiklik dengan inti cincin pirimidin, senyawa ini memiliki berbagai aktivitas biologis. Penelitian ini bertujuan untuk mensintesis senyawa turunan dihidropirimidinon, yaitu etil 4-(4-etoksi-3,5-dimetilfenil)-6-metil-2-okso-1,2,3,4-tetrahidropirimidin-5-karboksilat (A2), melalui reaksi Mitsunobu dan melakukan pengujian sitotoksik terhadap sel kanker payudara T47D. Sintesis dimulai dari senyawa etil 4- (4-hidroksi-3,5- dimetilfenil) -6-metil-2-okso- 1,2,3,4- tetrahidropirimidin-5-karboksilat (M1), yang dihasilkan melalui reaksi Biginelli dengan mereaksikan bahan utama aldehid,urea dan etil asetoasetat. Sintesis dilanjutkan dengan menggunakan reaksi Mitsunobu bersama etanol untuk memperoleh senyawa A2. Hasil dari  sintesis dilakukan karakterisasi menggunakan instrumen FTIR dan LC-MS. Karakterisasi menunjukkan adanya gugus khas hasil sintesis yaitu eter (C-O) pada bilangan gelombang 1042,31 cm⁻¹ dan massa molekul A2 sebesar 375,23 m/z. Pengujian aktivitas sitotoksik menggunakan metode MTT assay memberikan hasil bahwa nilai IC₅₀ senyawa A2 adalah 270,48 µg/mL, yang tergolong aktivitas lemah dibandingkan kontrol positif doxorubicin (IC₅₀ = 3,33 µg/mL). Berdasarkan hasil penelitian ini, senyawa A2 masih memerlukan pengembangan dan pengkajian lebih lanjut untuk meningkatkan potensi sitotoksiknya sebagai senyawa baru obat antikanker.
Co-Authors Fauzi Ahmad Muda Hakimah, Wafiq Kholifatul Ramadhan, Muhammad Reza